J Biol Chem, Vol. 275, Issue 3, 1930-1936, January 21, 2000
The Amino Terminus of the Fourth Cytoplasmic Loop of Rhodopsin
Modulates Rhodopsin-Transducin Interaction*
Ethan P.
Marin
,
A. Gopala
Krishna
§,
Tatyana A.
Zvyaga
§¶,
Juergen
Isele
,
Friedrich
Siebert
, and
Thomas P.
Sakmar
§**
From the § Howard Hughes Medical Institute,
Laboratory of Molecular Biology and Biochemistry, The
Rockefeller University, New York, New York 10021 and the
Institut für Biophysik und Strahlenbiologie der
Universität Freiburg, Albertstrasse 23, D-79104 Freiburg, Germany
 |
ABSTRACT |
Rhodopsin is a seven-transmembrane helix receptor
that binds and catalytically activates the heterotrimeric G protein
transducin (Gt). This interaction involves the
cytoplasmic surface of rhodopsin, which comprises four putative loops
and the carboxyl-terminal tail. The fourth loop connects the carboxyl
end of transmembrane helix 7 with Cys322 and
Cys323, which are both modified by membrane-inserted
palmitoyl groups. Published data on the roles of the fourth loop in the
binding and activation of Gt are contradictory. Here, we
attempt to reconcile these conflicts and define a role for the fourth
loop in rhodopsin-Gt interactions. Fluorescence experiments
demonstrated that a synthetic peptide corresponding to the fourth loop
of rhodopsin inhibited the activation of Gt by rhodopsin
and interacted directly with the
subunit of Gt. A
series of rhodopsin mutants was prepared in which portions of the
fourth loop were replaced with analogous sequences from the
2-adrenergic receptor or the m1 muscarinic receptor.
Chimeric receptors in which residues 310-312 were replaced could not
efficiently activate Gt. The defect in Gt
interaction in the fourth loop mutants was not affected by preventing
palmitoylation of Cys322 and Cys323. We suggest
that the amino terminus of the fourth loop interacts directly with
Gt, particularly with G
t, and with other
regions of the intracellular surface of rhodopsin to support
Gt binding.
 |
INTRODUCTION |
Rhodopsin, the dim-light photoreceptor of the rod cell, is a
prototypical member of the superfamily of G protein-coupled receptors (GPCRs)1 (1, 2). Following
exposure to light, rhodopsin assumes an active signaling conformation,
metarhodopsin II (MII). MII can bind and catalytically activate the
retinal heterotrimeric G protein, transducin (Gt).
Gt is composed of a guanine-nucleotide binding
subunit
(G
t), and a functional heterodimer of
and
subunits (G
t). Interaction of the trimer with MII
promotes the release of GDP from G
t, leading to the
formation of a stable MII-G
t(empty pocket) complex. The
subsequent binding of GTP activates G
t, leading to its
dissociation from the receptor and from G
t. The
activated G
t binds and activates its effector, cyclic
GMP phosphodiesterase.
The molecular structure of the complex between rhodopsin and
Gt, and the mechanism by which rhodopsin catalyzes
nucleotide exchange, are not understood in detail. Numerous studies
have localized the Gt-binding site to the cytoplasmic
surface of rhodopsin. The cytoplasmic surface is composed of four loops
(Fig. 1) and a carboxyl-terminal tail.
The first (C1), second (C2), and third (C3) cytoplasmic loops connect
adjacent transmembrane (TM) helices. The fourth cytoplasmic loop (C4)
is unique in that it is bounded by a helix only at its amino terminus;
its carboxyl terminus is formed by the insertion of two palmitoyl
groups into the membrane bilayer (3). The palmitoyl groups are attached
to Cys322 and Cys323 via thioester linkages (4,
5). The carboxyl-terminal tail is the region distal to
Cys322 and Cys323.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of bovine
rhodopsin. Seven putative TM helices are depicted as for previous
models of GPCRs. The amino terminus and intradiscal surface are toward
the bottom, and the carboxyl terminus and cytoplasmic
surface is toward the top of the figure. The intradiscal and
cytoplasmic loops are not drawn to scale. The loop C4 is defined as the
12 amino acids beginning with Asn310, at the membrane
border of the TM helix 7, and ending with Cys322 and
Cys323. Both of these cysteines are palmitoylated (4, 5),
and the palmitoyl groups are inserted into the membrane (3).
|
|
Considerable evidence has implicated C-2 and C-3 as participating in
the complex with Gt (6-9). However, the literature
addressing the role of C4 in interactions with Gt is
contradictory. Studies have shown that peptides derived from C4 can
disrupt the stabilization of MII by Gt (6), interfere with
rhodopsin-stimulated GTPase activity of Gt (10), and bind
directly to a fluorescently labeled G
t and prevent
G
t-rhodopsin interactions (11). In contrast, truncation of rhodopsin following Asn315, in the middle of
C4, does not impair Gt activation (12). Since truncation at
the beginning of C4 precluded proper expression and/or processing of
rhodopsin, a follow-up study examined a series of single and double
mutations in the amino-terminal half of C4, from Asn310
through Asn315. None of the mutations was found to disrupt
Gt activation, leading to the conclusion that C4 is not
required for productive interactions with Gt (13).
Here we have carefully re-examined and defined the role of the C4 loop
in rhodopsin-Gt interactions. We used fluorescence spectroscopy to demonstrate that a synthetic peptide corresponding to
C4 of bovine rhodopsin, rho(310-321), binds to Gt and free G
t. Furthermore, we demonstrate the potent inhibition of
rhodopsin-catalyzed Gt activation by rho(310-321). We also
prepared and characterized a series of site-directed mutants of bovine
rhodopsin with alterations of the C4 loop. These data show that when
either the entire C4 loop or a tripeptide
(Asn310-Lys311-Gln312) at the amino
terminus of the loop is replaced with the analogous sequence of the
2-adrenergic receptor (
2-AR), the
Gt-activating function of rhodopsin is diminished. Neither
replacement of the carboxyl-terminal half of the loop, nor removal of
the palmitoylation sites disrupt Gt activation. We conclude
that the C4 loop is involved in mediating interactions between
rhodopsin and Gt.
 |
EXPERIMENTAL PROCEDURES |
Preparation of Peptides--
Peptides were synthesized at the
Rockefeller University Protein/DNA Technology Center and HHMI
Biopolymer Facility by solid phase technique using Fmoc
(N-(9-fluorenyl)methoxycarbonyl) chemistry. All peptides
were prepared with free amino termini, and were amidated at the
carboxyl termini. The peptides were purified by high performance liquid
chromatography and characterized by mass spectrometry. The names and
amino acid sequences of the peptides used in this study are the
following: rho(132-144), AIERYVVVCKPMS; rho(240-252), SATTQKAEKEVTR;
rho(310-321), NKQFRNCMVTTL; rho(313-321), FRNCMVTTL; rho(310-321)scr, TLTVNMKCQNFR; rho(310-321)SPD, SPDFRNCMVTTL.
Preparation of Gt, G
t, and
G
t--
Gt was prepared from frozen
bovine retinas (Lawson, Inc., Lincoln, NE) using standard techniques
(14, 15). Specific activities of Gt samples were determined
by spectrofluorometric titration, as described previously (16).
G
t and G
t were isolated from holo-Gt essentially according to published methods (17)
using a Hitachi LC-organizer high performance liquid chromatography system with a 1-ml Hi-Trap Blue-Sepharose column (Amersham Pharmacia Biotech). The proteins were eluted from the column by applying a 0-2
M NaCl gradient. Protein concentrations were determined using the Bio-Rad protein assay reagent according to the
manufacturer's instructions. The subunits were stored at
20 °C in
a 50% glycerol buffer until use.
Measurement of Intrinsic Fluorescence of Gt,
G
t, and G
t--
Fluorescence measurements
were done on a Spex Fluorolog 3-11
3 spectrofluorometer equipped
with a 450 W Xenon arc lamp. All fluorescence experiments were
performed in 10 mM Tris-HCl buffer (pH 7.2) containing 100 mM NaCl, 2 mM MgCl2, 1 mM dithiothreitol, 5 µM GDP, and 0.01% (w/v)
dodecyl maltoside. Spectra were recorded at 10 °C in a 4 × 4-mm quartz cuvette. Protein fluorescence was obtained by exciting at
295 nm and monitoring emission from 315 to 450 nm. The excitation and
emission slit bandpass were 1.5 and 5 nm, respectively. Titration
experiments were typically performed by adding 10-µl aliquots of the
peptide from a stock solution of 250 µM to a protein
solution of 200 nM.
Preparation of Rhodopsin Mutants--
Site-directed mutagenesis
was achieved primarily by using restriction fragment replacement (18)
in a synthetic rhodopsin gene (19) cloned into a eukaryotic expression
vector (20). Mutants CTr1 and CTr3 were constructed by substituting the
BspEI-SalI restriction fragment with a synthetic
duplex containing the desired codon alterations; mutant CTr2 involved a
similar substitution of the ApaI-SalI fragment.
Mutants CTr4 and the Lys311 point mutations involved
substitution of an ApaI-BspEI fragment. The
mutant CysXV (C322S/C323S) was constructed by substituting the
XhoI-BstEII fragment of the rhodopsin gene into
CysXIII (C140S/C316S/C322S/C323S). CysXIII was prepared by substituting
the BspEI-SalI fragment of a C140S mutant (21)
with a synthetic fragment that contained the appropriate codon
alterations for C316S, C322S, and C323S. The combination mutant
CTr4/CysXV was prepared by cloning the XhoI-BstEII fragment of CTr4 into a
XhoI-BstEII digested CysXV vector. Cell culture,
transfection, and immunoaffinity purification procedures have been
described elsewhere (22-24). Membranes from transfected cells were
prepared prior to regeneration with 11-cis-retinal using
sucrose density gradient centrifugation, as described previously (25).
Fluorescence Gt Activation Assay--
The assay was
performed essentially as described (16), using 250 nM
Gt and 1 nM rhodopsin or mutant pigment.
Peptide competition assays were performed with 200 nM
Gt and 1 nM purified COS cell-expressed rhodopsin from which 1D4 peptide introduced in the purification procedure was removed by gel filtration on a G-50 Nick column (Amersham
Pharmacia Biotech). The appropriate concentration of peptide was added
from a 15 mM stock solution and preincubated with
Gt for 30 min before the start of the assay.
Measurement of [3H]Palmitic Acid
Incorporation--
Opsin was metabolically labeled with
[3H]palmitic acid (NEN Life Science Products Inc.,
Boston, MA) essentially as described previously (26). Briefly, 48 h post-transfection, COS cells were grown for 8 h in serum-free
media. The cells were then incubated for 30 min in 1% serum, followed
by 2 h in 1% serum supplemented with 100 µCi/ml
[3H]palmitic acid (43 Ci/mmol). Cells were washed with
phosphate-buffered saline, harvested, and solubilized in 0.1% (w/v)
dodecyl maltoside solution. The detergent extracts were incubated
overnight with resin conjugated with 1D4 monoclonal antibody as used in
the standard rhodopsin purification procedure (27). The resin was
washed extensively, as monitored by the decreasing tritium counts
present in successive washes. Opsin was eluted from the resin by
incubation with wash buffer containing the 1D4 peptide. The relative
amounts of [3H]palmitic acid incorporated into the eluted
samples were analyzed by scintillation counting.
 |
RESULTS |
Inhibition of Gt Activation by Synthetic Peptides
Corresponding to Cytoplasmic Loops of Rhodopsin--
Peptides derived
from the C2, C3, and C4 loops of rhodopsin have been shown to disrupt
the ability of Gt to stabilize MII as measured by an
extra-MII assay (6). We examined whether similar peptides could also
disrupt the activation of Gt by catalytic amounts of
solubilized rhodopsin in a fluorescence activation assay. In Fig.
2, a dose-dependent decrease
in the rate of Gt activation is observed in the presence of
synthetic peptides derived from the amino terminus of C2
(rho(132-144)), the carboxyl terminus of C3 (rho(240-252)), and C4
(rho(310-321)). The effective concentration at 50% inhibition
(IC50) for all peptides was in the 0.1-0.3 mM range; all peptides inhibited activation completely at concentrations
1 mM. A C1-derived peptide, rho(61-75), only modestly
inhibited transducin activation at 1 mM (not shown).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Peptides derived from the second, third, and
fourth intracellular loops of rhodopsin inhibit activation of
Gt by rhodopsin. Each panel shows the relative initial
rate of Gt activation as a function of peptide
concentration. Activation rates were determined using a fluorescence
assay of Gt activation (16). The peptide used in each
experiment is described in the lower left hand corner of the
corresponding panel. All three peptides completely inhibited activation
of Gt, with IC50 values in the 0.1-0.3
mM range. A peptide derived from the first intracellular
loop only moderately inhibited Gt activation at a
concentration of 1 mM (not shown). Each panel represents
data from a single set of experiments, which was repeated at least
twice with similar results.
|
|
A Synthetic Peptide Derived from C4 of Rhodopsin, Rho(310-321),
Alters the Fluorescence Emission Wavelength Maximum of
G
t but Not of G
t--
In an effort to
characterize the interactions of C4 with Gt, the intrinsic
fluorescence emission spectra of G
t and
G
t were collected in the presence of increasing
concentrations of rho(310-321). A significant red shift (7.8 ± 0.3 nm, n = 4) in the
max of tryptophan emission of G
t was observed in the presence of 45 µM peptide (Fig.
3A). The shift was accompanied
by a modest (~10%) increase in intensity. These spectral changes are
indicative of a change in the molecular environment of at least one of
the two tryptophans of G
t caused by the binding of the
peptide. The extent of the red shift was dependent on the concentration
of peptide (Fig. 3A, inset). In contrast, the
max of tryptophan fluorescence emission of
G
t was only minimally (1.0 ± 0.3 nm,
n = 4) affected by the peptide (Fig. 3B).
These data suggest that the peptide does not bind to free
G
t, but they do not rule out binding in a manner that
does not alter the molecular environment of enough of its 8 intrinsic
tryptophans to allow for spectroscopic detection. The emission spectrum
of holo-Gt was red shifted by approximately 4 nm in the
presence of the peptide (data not shown), which is consistent with
peptide interaction with G
t but not G
t
in the context of the heterotrimer. The effects of three additional
peptides on the
max of G
t emission were
examined. The peptides, which were derivatives of rho(310-321), were:
(a) rho(313-321), in which residues 310, 311, and 312 were
not present; (b) rho(310-321)scr in which the
order of the amino acids was scrambled; and (c)
rho(310-321)SPD in which the first three positions of the
peptide were changed from NKQ to SPD. The sequence of
rho(310-321)SPD is derived from the rhodopsin mutant CTr4
(Fig. 4). The peptides rho(313-321) and
rho(310-321)scr did not affect the
max of
G
t emission, whereas rho(310-321)SPD caused
a ~4-nm red shift, with no change in fluorescence intensity (data not
shown). As an additional control, the
max of the
emission spectrum of bovine serum albumin was shown to be insensitive
to the presence of rho(310-321) (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of rho(310-321) on the intrinsic
fluorescence of G t and
G t subunits.
Fluorescence emission spectra were collected using an excitation
wavelength of 295 nm. A, fluorescence emission
spectra of G t (200 nM) before (solid
line) and after (dashed line) incubation with the
rhodopsin C4 peptide, rho(310-321) (45 µM). The
inset shows the fluorescence emission max of
G t as a function of rho(310-321) concentration. The
mean maximum  max ± S.E. was 7.8 ± 0.3 nm
(n = 4). B, fluorescence emission
spectra of G t (200 nM) before
(solid line) and after (dashed line) incubation
with rho(310-321) (45 µM). Inset shows the
fluorescence emission max of G t as a
function of rho(310-321) concentration. The mean maximum
 max ± S.E. was 1.0 ± 0.3 nm (n = 4). Data shown are representative of at least four independent and
reproducible experiments.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 4.
Amino acid sequences of the fourth loop of
bovine rhodopsin, human 2-AR,
human m1-MR, and fourth loop mutants of rhodopsin. The amino acid
sequence of each position in the fourth loop is shown using the
standard single letter amino acid code. The numbering of the positions
is from bovine rhodopsin. Regions that were replaced or altered in the
creation of mutants are highlighted in gray.
|
|
Preparation of Substitution Mutants in C4 of Rhodopsin--
Three
rhodopsin mutants were prepared in which portions of C4 were replaced
with sequences from analogous segments of the
2-AR or
the m1-muscarinic receptor (m1-MR) (Fig. 4). These two receptors were
chosen because they have fourth loops of similar lengths to that of
rhodopsin and at least one cysteine homologous to Cys322 or
Cys323 of rhodopsin. The
2-AR has been shown
to be palmitoylated (28), while this modification in the m1-MR is
inferred to be very likely because of the presence of a Cys residue at
the required location. Furthermore, these receptors bind G protein
types not related to Gt, which is a member of the
Gi/o class. The m1-MR couples to Gq, and the
2 AR couples to Gs.
In mutants CTr1 and CTr2, portions of C4 are replaced with sequence
derived from the
2-AR (Fig. 4). CTr1 involves
replacement of the carboxyl-terminal half of the loop, while the entire
fourth loop is replaced in CTr2. Only a carboxyl-terminal replacement was constructed with the m1-MR (CTr3), since the amino-terminal halves
of the C4 loops of rhodopsin and m1-MR are nearly identical. The
chimeric C4 mutant approach offers several advantages. For example,
since the replacements are relatively long, and the substituted sequence is derived from receptors that couple to Gs or
Gq, the sensitivity of observing a relevant disruption in G
protein coupling is high. Additionally, since the fourth loops of the
2-AR, m1-MR, and rhodopsin are of comparable length, the
expression, folding, and palmitoylation of the chimeric fourth loop
mutants should not be disrupted. Therefore, the confidence of
attributing a loss-of-function phenotype to a specific defect in
Gt coupling is high.
The analysis of CTr1, CTr2, and CTr3 described below pointed toward the
involvement of the amino-terminal part of C4 in Gt interactions. To further examine this region, mutant CTr4 was constructed in which only those positions that differ between CTr1 and
CTr2 (i.e. 310, 311, and 312) were replaced (Fig. 4). In
addition, a series of point mutations in which Lys311 was
replaced by residues with a variety of physicochemical properties were
constructed: K311P, K311S, K311R, and K311W. Position 311 lies in the
center of a proposed helical extension of TM7 (29, 30). These mutants
were designed specifically to test and control for the possible role of
a helix-altering proline in the 311 position in mutant CTr2. Two
additional mutants were constructed to assess the role of
palmitoylation in the function of C4. In CysXV (C322S/C323S) the sites
of palmitoylation were removed, and in Ctr4/CysXV, the CTr4 and CysXV
replacements were combined. The mutant CysXV has been previously
described and characterized in a detergent-solubilized Gt
activation assay (26). The mutant CTr4/CysXV was used to test whether
the effects of preventing palmitoylation were different in the
background of a mutated C4 as compared with rhodopsin.
The mutants were transiently expressed in COS cells and regenerated
with 11-cis-retinal to yield pigments. The mutant pigments were either purified in dodecyl maltoside detergent or isolated in cell
membrane preparations. UV-visible spectra taken on purified samples in
the dark showed that each mutant pigment had a
max value
of 500 nm, identical to that of rhodopsin prepared under the same
conditions (Table I). Upon illumination,
mutants CTr1, CTr2, and CTr3 formed MII-like pigments with
max values of 380 nm. Acid denaturation of the
photolyzed pigments revealed that the Schiff base bonds of the mutants
were at least as stable as that of rhodopsin (data not shown).
Activation of Gt by Solubilized Purified Recombinant
Pigments--
The ability of the C4 loop substitution mutants to
activate purified bovine Gt was measured in a kinetic
fluorescence assay. The activation of Gt was observed as an
increase in the intrinsic tryptophan fluorescence of G
t
upon binding of GTP
S (16). The initial rate of GTP
S uptake by
Gt catalyzed by each mutant was normalized to that of
rhodopsin (Fig. 5). Mutants CTr1 and
CTr3, in which the carboxyl-terminal half of the loop was replaced, displayed similar initial rates to that of rhodopsin. However, CTr2, in
which the entire loop was replaced, displayed a reduced initial rate.
The CTr4 mutant, in which only a tripeptide in the amino-terminal part
of the loop was replaced with
2-AR sequence, was also
deficient in activating Gt. The level of activity was comparable to that of CTr2. None of the Lys311 point
mutants was defective in Gt activation. The
non-palmitoylated CysXV mutant exhibited similar activity to that of
rhodopsin in the detergent assay. When assayed in membranes, CysXV was
slightly hyperactive (data not shown). The activity of the combination mutant CTr4/CysXV was similar to that of CTr4.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
Rates of Gt activation catalyzed
by solubilized, purified recombinant pigments. Samples of
rhodopsin and C4 rhodopsin mutants were expressed in COS cells,
solubilized in dodecyl maltoside, and purified by an immunoaffinity
procedure as described under "Experimental Procedures." The rates
of Gt activation catalyzed by each sample were determined
by linear regression through the first 30-60 s of data collected in a
fluorescence activation assay (16). Each assay contained 1 nM rhodopsin or mutant, 250 nM Gt,
and 5 µM GTP S in a volume of 1.5 ml. The
bars represent the mean rate, normalized to that of
rhodopsin. Error bars depict the standard error of the mean.
The data are presented numerically in Table I. Those mutants in which
residues 310, 311, and 312 of rhodopsin are replaced with the analogous
sequence of the 2-AR (i.e. CTr2, CTr4, and
CTr4/CysXV) are deficient in Gt activation.
|
|
Characterization of Pigment-catalyzed GTP
S Uptake by
G
t As a Function of G
t
Concentration--
Efficient activation of G
t is known
to require the presence of G
t (31). A previous study
of a peptide derived from the C4 loop of rhodopsin suggested that this
region binds to G
t (11). Therefore, the reduced
activation of Gt by the mutant CTr2 might be a result of
disruption of the G
t-binding site on rhodopsin. To
test this hypothesis, the rate of Gt activation by
solubilized, COS cell expressed rhodopsin (1 nM) or CTr2 (3 nM) was measured as a function of the concentration of
G
t. Higher concentrations of CTr2 were necessary in
this experiment due to its reduced activity. Fig.
6 shows the change in fluorescence over
time due to rhodopsin- or CTr2-catalyzed GTP
S uptake by G
t in the presence of different concentrations of
G
t. The intrinsic tryptophans of G
t
affected only the background level of fluorescence, which is normalized
in Fig. 6. If the defect in CTr2 were solely attributable to decreased
binding of G
t, then the concentration of
G
t at which half-maximal activity was observed would
likely be significantly higher for CTr2 than for rhodopsin.
Additionally, one might expect the relative defect in activation rate
of CTr2 to be reduced at high concentrations of G
t.
The data do not reveal a significant difference between rhodopsin and
CTr2 in the effect of G
t concentration on
G
t activation, nor does the activity of CTr2 approach
that of rhodopsin even at a 2:1
(G
t:G
t) stoichiometric excess (Fig.
6).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 6.
The relative rates of pigment-catalyzed
GTP S uptake by
G t as a function of
G t concentration are
similar for both rhodopsin and CTr2. The rate of Gt
activation by solubilized, COS cell-expressed pigment was measured as a
function of the concentration of G t. The top
panel shows fluorescence activation traces of 250 nM
G t in the presence of 25-500 nM
G t, and catalyzed by 1 nM rhodopsin. Each
trace depicts the change in fluorescence emission intensity following
the addition of GTP S at 200 s. The background fluorescence
emission is normalized to zero. The concentration of
G t in each trace is indicated in the column at
right, in the same order that the traces are displayed. The
inset is a plot of activation rate, determined from the
initial slopes of the activation traces, versus
concentration of G t. The data are fit with a
two-parameter hyperbolic function. The bottom panel is
identical to the top, except that the experiments were conducted with 3 nM CTr2. The data are from a single experiment that was
repeated twice with similar results. The similarity of the
G t concentration dependence for rho and CTr2 argues
against the hypothesis that the defect in CTr2 is attributable solely
to disruption of the G t-binding site (see text for
further discussion).
|
|
Palmitoylation of CTr1, Ctr2, and CTr4--
We investigated
whether replacing portions of the fourth loop with
2-AR
sequence disrupted palmitoylation of mutants CTr1, CTr2, and CTr4. The
incorporation of [3H]palmitic acid present in the cell
media during transfection into CTr1, CTr2, CTr4, and rhodopsin was
comparable (Table I). The levels of incorporation were severalfold
higher than the incorporation associated with CysXV, which has been
reported not to be palmitoylated (26).
Amino Acid Sequence Analysis of Vertebrate Opsins--
The
sequence alignments and analyses available in the G Protein-coupled
Receptor Data Base (GPCRDB) were used to examine the conservation of C4
residues in GPCRs (32). Among the 86 vertebrate opsins in the data
base, the residues in the amino-terminal half of C4 were found to be
nearly 100% conserved (Fig. 7). In
contrast, the carboxyl-terminal half of the loop is only ~65%
conserved.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 7.
The amino-terminal half of the fourth loop of
rhodopsin is more conserved than the carboxyl-terminal half within the
family of vertebrate opsins. The conservation of each position
within loop C4 of rhodopsin was analyzed in 86 vertebrate opsin
sequences. The alignments and the determination of the variability at
each position were obtained from the G Protein-coupled Receptor Data
Base (32). The labels on the x axis indicate the
consensus amino acid at each position, using bovine rhodopsin
numbering. A variability index of 100 means 100% conservation; the
lower the number, the greater the variety of residues found at that
particular position. The residues in the amino-terminal half of the
loop are nearly 100% conserved, whereas those at the carboxyl-terminal
half are only ~65% conserved. This pattern of conservation
corresponds to the importance of the amino-terminal half of the loop in
Gt activation.
|
|
 |
DISCUSSION |
Significant efforts have been directed toward elucidating the
regions of rhodopsin involved in binding and activating Gt
(for reviews, see Ref. 2, 33, and 34). A variety of experiments using
peptide competition, mutagenesis, and antibody-based approaches have
defined the importance of the intracellular surface, and in particular,
loops C2 and C3 in mediating interactions with Gt.
Published reports regarding the role of loop C4 are contradictory. Studies based on peptides derived from C4 have suggested the importance of this region (6, 10), but a combination of site-directed mutagenesis
and truncation of C4 appeared to rule out an important function for the
region in Gt activation (12, 13). Our data demonstrate and
characterize the importance of the amino-terminal part of the fourth
loop, and suggest the role it plays in rhodopsin-Gt interactions.
Loop C4 of Rhodopsin Is Involved in the Activation of
Gt--
Several different experimental approaches in this
report corroborate the importance of the fourth loop of rhodopsin in
interactions with Gt. A peptide derived from C4,
rho(310-321), can inhibit the catalysis of Gt activation
by rhodopsin. Previously, an identical peptide has been reported to
inhibit the binding of Gt to rhodopsin as measured by an
extra-MII assay (6). Our results extend and confirm this observation by
demonstrating that the peptide is active at similar concentrations in
the fluorescence activation assay (Fig. 2). Significantly, the potency
of rho(310-321) was comparable to that of peptides derived from very
well characterized G protein-interacting regions, including the highly
conserved Glu-Arg-Tyr sequence in the C2-derived rho(132-144) peptide.
Additionally, rho(310-321) induces a red shift in the fluorescence
emission spectrum of G
t (Fig. 3), which is evidence that
the peptide can bind directly to the G
t subunit. The
relevance of studies with the isolated C4-derived peptide to the
function of C4 in the intact receptor is supported by the report that a
rho(306-348) peptide assumed a defined structure in solution (29).
The results of the mutagenesis data strongly support and clarify the
involvement of the fourth loop in Gt activation. In
particular, the data localize the important region to the amino
terminus of C4, as shown by the striking decrease in the rate of
Gt activation by the mutants in which residues 310-312 are
replaced with
2-AR sequence (Fig. 5). Osawa and Weiss
(13) argued against involvement of this region based on the wild-type
phenotype of N310A, K311A, and Q312A point mutants. However, a recent
report (35) corroborates our findings by identifying a mutation in the
amino terminus of C4 (N310C) that can disrupt Gt
activation. The precise role of Asn310 in Gt
coupling appears complex, and additional work is underway that focuses
exclusively on this residue.
Sequence analysis also supports the importance of the amino terminus of
the C4 loop in receptor function. The amino terminus of C4 is nearly
100% conserved within the vertebrate opsins, whereas the
carboxyl-terminal half of the loop is only ~65% conserved (Fig. 7).
Furthermore, the asparagine in position 310 is very highly conserved
within the large biogenic amine family of receptors, with the exception
of the non-
2-ARs, where it nearly always is a serine.
This latter observation suggests that the amino-terminal part of the
fourth loop may be important in GPCRs other than opsins. Indeed,
mutagenesis experiments in this region of the fourth loop identified it
as critical for receptor-G protein interactions in the
2-AR (36, 37).
Several reports have suggested that accessibility to regions in the
fourth loop are specifically modulated by photoactivation of rhodopsin,
an observation consistent with the regulated involvement of C4 in
Gt activation. The cytoplasmic end of TM helix 7 has been
shown to become more accessible following light activation of rhodopsin
(38), and spin labels attached to positions 316 (39) and 313 (30) in
the middle of C4 undergo increased mobility after photolysis.
Additionally, a spin label at Cys316 was reported to move
apart from a label at position 65, at the amino terminus of the TM
helix 1, upon MII formation (40).
Factors Affecting the Structure of the C4 Loop Region--
We
examined several factors that potentially affect the structure of C4,
including the palmitoylation of Cys322 and
Cys323, the integrity of a proposed helical extension of
TM7, and the presence of a membrane environment. The palmitoylation of
Cys322 and Cys323 does not appear to affect the
function of the amino-terminal part of the loop. Both CTr4 and CTr2 are
palmitoylated (Table I) despite alterations in amino acids in the
vicinity of the acylation site. However, the non-palmitoylated
combination mutant CTr4/CysXV is essentially indistinguishable from
CTr4 in detergent assays. In membranes, CysXV is slightly more active
than rhodopsin, and CTr4/CysXV is slightly more active than CTr4 (not
shown). Both observations corroborate previous reports that a
nonpalmitoylated mutant was similar to rhodopsin in detergent solution
(26), and that chemical depalmitoylation increased activity of
rhodopsin when assayed in rod outer segment membranes (41). Given that residues 310-312 are located adjacent to the membrane border of the TM
helix 7, it seems plausible that their structure is unaffected by the
membrane anchoring of Cys322 and Cys323. The
same reasoning might explain why truncation of rhodopsin following
Asn315 does not diminish Gt activation (12).
Furthermore, C4 may form a loop in the absence of palmitoylation, as
suggested by the NMR structure of a fourth loop peptide (29). The
mechanism of hyperactivity of non-palmitoylated rhodopsin that has been
observed in membranes appears to be unrelated to the function of the
amino terminus of C4.
The TM helix 7 is likely to extend beyond the membrane border, based on
experimental (29, 30) and theoretical (42) grounds. The TM2 (43), TM4,
and TM5 (44) helices have all been reported to extend into the aqueous
phase. The proline in position 311 of CTr2 and CTr4 might disrupt a
helical extension of TM helix 7, leading to the observed phenotype. But
the K311P point mutation does not resemble the 310-312 mutation of
CTr4 in Gt activation assays, indicating that perturbation
of the proposed helical extension does not impair G protein activation.
The Role of the C4 Loop Involves Modulation of
Rhodopsin-Gt Interactions--
We propose that the role of
C4 is to modulate, in conjunction with other structures, the binding
site for Gt. We favor this interpretation rather than those
in which C4 serves as the sole binding site or participates
mechanistically in the catalysis of nucleotide exchange because:
(a) residual Gt activation was observed with the
CTr2 and CTr4 mutants, (b) point mutations at the 311 position did not affect activation, (c) the amino-terminal C4 sequence of rhodopsin is highly, but not absolutely, conserved in
other opsins and in certain other GPCRs (Fig. 7), and (d)
the substitution of
2-AR sequence into C4 does not allow
rhodopsin to activate Gs (data not shown). The modulatory
functions of C4 appear to be mediated both by contacts with
Gt and by allosteric interactions with other regions of the receptor.
Specific interaction between C4 and Gt is indicated most
directly by the rho(310-321)-Gt
interaction observed by
fluorescence emission spectroscopy (Fig. 3). Direct contacts are also
suggested by the inhibition of rhodopsin-catalyzed Gt
activation in the presence of rho(310-321), an observation plausibly
explained by binding of the peptide to the G protein, and occupancy of
a receptor contact site (Fig. 2). Which part of the heterotrimer is
binding to the C4 loop? A C4-derived peptide, rho(310-324), has been
reported to bind G
t (11). However, the similarity of
the activation rate versus G
t
concentration profiles for rhodopsin and CTr2, and the failure of high
concentrations of G
t to fully rescue CTr2 activity
(Fig. 6), argue against the fourth loop as acting solely as a
G
t-binding site. Furthermore, the direct binding of
rho(310-321) to G
t (Fig. 3) demonstrates that C4 is
involved with G
t binding in addition to, or even instead
of, G
t binding. Perhaps C4 binds G
t
directly, and allosterically regulates other regions of the receptor
involved in G
t binding.
The data in this report demonstrate a conclusive role for the amino
terminus of C4 of rhodopsin in Gt interactions. We suggest that this region interacts directly with Gt, particularly
with G
t, and with other regions of the intracellular
surface to support Gt binding. In the following paper, we
study a subset of mutant receptors described here using a biophysical
assay that detects binding of Gt or peptides derived from
Gt subunit sequences (45).
 |
ACKNOWLEDGEMENTS |
We thank Dr. Steve Lin, Manija Kazmi,
Wing-Yee Fu, Cliff Sonnenbrot, and Carol Valli for assistance with
these studies and their interpretation. We also thank Dr. P. Yeagle for
providing the coordinates of the NMR structure of the rho(306-348) peptide.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Training Grants GM07739, EY07138, and GM07982 and by Deutsche Forschungsgemeinschaft Grant AZ Si-278/16-1 (to F. S.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This article is dedicated by A. G. K. to Prof. D. Balasubramanian on the occasion of his 60th birthday.
¶
Current address: Bristol-Myers Squibb, Wallingford, CT 06492.
**
Associate Investigator of the Howard Hughes Medical Institute. To
whom correspondence should be addressed: Box 284, Rockefeller University, 1230 York Ave., New York, NY 10021. Tel.: 212-327-8288; Fax: 212-327-7904; E-mail: sakmar@rockvax.rockefeller.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
GPCR, G
protein-coupled receptor;
AR, adrenergic receptor;
C1, first
cytoplasmic loop of rhodopsin;
C2, second cytoplasmic loop of
rhodopsin;
C3, third cytoplasmic loop of rhodopsin;
C4, fourth
cytoplasmic loop of rhodopsin;
Gt, transducin;
G
t,
subunit of transducin;
G
t, 
heterodimer subunit of transducin;
MII, metarhodopsin II;
MR, muscarinic receptor;
TM, transmembrane;
GTP
S, guanosine
5'-3-O-(thio)triphosphate.
 |
REFERENCES |
| 1.
|
Sakmar, T. P.
(1998)
Prog. Nucleic Acids Res. Mol. Biol.
59,
1-34[Medline]
[Order article via Infotrieve]
|
| 2.
|
Helmreich, E. J.,
and Hofmann, K. P.
(1996)
Biochim. Biophys. Acta
1286,
285-322[Medline]
[Order article via Infotrieve]
|
| 3.
|
Moench, S. J.,
Moreland, J.,
Stewart, D. H.,
and Dewey, T. G.
(1994)
Biochemistry
33,
5791-5796[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Papac, D. I.,
Thornburg, K. R.,
Bullesbach, E. E.,
Crouch, R. K.,
and Knapp, D. R.
(1992)
J. Biol. Chem.
267,
16889-16894[Abstract/Free Full Text]
|
| 5.
|
Ovchinnikov, Y. A.,
Abdulaev, N. G.,
and Bogachuk, A. S.
(1988)
FEBS Lett.
230,
1-5[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Koenig, B.,
Arendt, A.,
McDowell, J. H.,
Kahlert, M.,
Hargrave, P. A.,
and Hofmann, K. P.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
6878-6882[Abstract/Free Full Text]
|
| 7.
|
Franke, R. R.,
Konig, B.,
Sakmar, T. P.,
Khorana, H. G.,
and Hofmann, K. P.
(1990)
Science
250,
123-125[Abstract/Free Full Text]
|
| 8.
|
Franke, R. R.,
Sakmar, T. P.,
Graham, R. M.,
and Khorana, H. G.
(1992)
J. Biol. Chem.
267,
14767-14774[Abstract/Free Full Text]
|
| 9.
|
Borjigin, J.,
and Nathans, J.
(1994)
J. Biol. Chem.
269,
14715-14722[Abstract/Free Full Text]
|
| 10.
|
Takemoto, D. J.,
Morrison, D.,
Davis, L. C.,
and Takemoto, L. J.
(1986)
Biochem. J.
235,
309-312[Medline]
[Order article via Infotrieve]
|
| 11.
|
Phillips, W. J.,
and Cerione, R. A.
(1992)
J. Biol. Chem.
267,
17032-17039[Abstract/Free Full Text]
|
| 12.
|
Weiss, E. R.,
Osawa, S.,
Shi, W.,
and Dickerson, C. D.
(1994)
Biochemistry
33,
7587-7593[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Osawa, S.,
and Weiss, E. R.
(1994)
Mol. Pharmacol.
46,
1036-1040[Abstract]
|
| 14.
|
Kuhn, H.
(1980)
Nature
283,
587-589[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Fung, B. K.,
Hurley, J. B.,
and Stryer, L.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
152-156[Abstract/Free Full Text]
|
| 16.
|
Fahmy, K.,
and Sakmar, T. P.
(1993)
Biochemistry
32,
7229-7236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Shichi, H.,
Yamamoto, K.,
and Somers, R. L.
(1984)
Vision Res.
24,
1523-1531[Medline]
[Order article via Infotrieve]
|
| 18.
|
Lo, K.-M.,
Jones, S. S.,
Hackett, N. R.,
and Khorana, H. G.
(1984)
Proc. Natl. Acad. Sci. U. S. A.
91,
2285-2289[Abstract/Free Full Text]
|
| 19.
|
Ferretti, L.,
Karnik, S. S.,
Khorana, H. G.,
Nassal, M.,
and Oprian, D. D.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
599-603[Abstract/Free Full Text]
|
| 20.
|
Franke, R. R.,
Sakmar, T. P.,
Oprian, D. D.,
and Khorana, H. G.
(1988)
J. Biol. Chem.
263,
2119-2122[Abstract/Free Full Text]
|
| 21.
|
Karnik, S. S.,
Sakmar, T. P.,
Chen, H. B.,
and Khorana, H. G.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8459-8463[Abstract/Free Full Text]
|
| 22.
|
Sakmar, T. P.,
Franke, R. R.,
and Khorana, H. G.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8309-8313[Abstract/Free Full Text]
|
| 23.
|
Min, K. C.,
Zvyaga, T. A.,
Cypess, A. M.,
and Sakmar, T. P.
(1993)
J. Biol. Chem.
268,
9400-9404[Abstract/Free Full Text]
|
| 24.
|
Han, M.,
Lin, S. W.,
Minkova, M.,
Smith, S. O.,
and Sakmar, T. P.
(1996)
J. Biol. Chem.
271,
32337-32342[Abstract/Free Full Text]
|
| 25.
| Han, M., and Sakmar, T. P. (2000) Methods Enzymol., in
press
|
| 26.
|
Karnik, S. S.,
Ridge, K. D.,
Bhattacharya, S.,
and Khorana, H. G.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
40-44[Abstract/Free Full Text]
|
| 27.
|
Oprian, D. D.,
Molday, R. S.,
Kaufman, R. J.,
and Khorana, H. G.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
8874-8878[Abstract/Free Full Text]
|
| 28.
|
O'Dowd, B. F.,
Hnatowich, M.,
Caron, M. G.,
Lefkowitz, R. J.,
and Bouvier, M.
(1989)
J. Biol. Chem.
264,
7564-7569[Abstract/Free Full Text]
|
| 29.
|
Yeagle, P. L.,
Alderfer, J. L.,
and Albert, A. D.
(1996)
Mol. Vis.
2,
12[Medline]
[Order article via Infotrieve]
|
| 30.
|
Altenbach, C.,
Cai, K.,
Khorana, H. G.,
and Hubbell, W. L.
(1999)
Biochemistry
38,
7931-7937[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Fung, B. K. K.
(1983)
J. Biol. Chem.
258,
10495-10502[Abstract/Free Full Text]
|
| 32.
|
Horn, F.,
Weare, J.,
Beukers, M. W.,
Horsch, S.,
Bairoch, A.,
Chen, W.,
Edvardsen, O.,
Campagne, F.,
and Vriend, G.
(1998)
Nucleic Acids Res.
26,
275-279[Abstract/Free Full Text]
|
| 33.
|
Wess, J.
(1997)
FASEB J.
11,
346-354[Abstract]
|
| 34.
|
Bourne, H. R.
(1997)
Curr. Opin. Cell Biol.
9,
134-142[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Cai, K.,
Klein-Seetharaman, J.,
Farrens, D.,
Zhang, C.,
Altenbach, C.,
Hubbell, W. L.,
and Khorana, H. G.
(1999)
Biochemistry
38,
7925-7930[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
O'Dowd, B. F.,
Hnatowich, M.,
Regan, J. W.,
Leader, W. M.,
Caron, M. G.,
and Lefkowitz, R. J.
(1988)
J. Biol. Chem.
263,
15985-15992[Abstract/Free Full Text]
|
| 37.
|
Liggett, S. B.,
Caron, M. G.,
Lefkowitz, R. J.,
and Hnatowich, M.
(1991)
J. Biol. Chem.
266,
4816-4821[Abstract/Free Full Text]
|
| 38.
|
Abdulaev, N. G.,
and Ridge, K. D.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12854-12859[Abstract/Free Full Text]
|
| 39.
|
Resek, J. F.,
Farahbakhsh, Z. T.,
Hubbell, W. L.,
and Khorana, H. G.
(1993)
Biochemistry
32,
12025-12032[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Yang, K.,
Farrens, D. L.,
Altenbach, C.,
Farahbakhsh, Z. T.,
Hubbell, W. L.,
and Khorana, H. G.
(1996)
Biochemistry
35,
14040-14046[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Morrison, D. F.,
O'Brien, P. J.,
and Pepperberg, D. R.
(1991)
J. Biol. Chem.
266,
20118-20123[Abstract/Free Full Text]
|
| 42.
|
Ben-Tal, N.,
Ben-Shaul, A.,
Nicholls, A.,
and Honig, B.
(1996)
Biophys. J.
70,
1803-1812[Abstract/Free Full Text]
|
| 43.
|
Farahbakhsh, Z. T.,
Ridge, K. D.,
Khorana, H. G.,
and Hubbell, W. L.
(1995)
Biochemistry
34,
8812-8819[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Altenbach, C.,
Yang, K.,
Farrens, D. L.,
Farahbakhsh, Z. T.,
Khorana, H. G.,
and Hubbell, W. L.
(1996)
Biochemistry
35,
12470-12478[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Ernst, O. P.,
Meyer, C. K.,
Marin, E. P.,
Henklein, P.,
Fu, W. Y.,
Sakmar, T. P.,
and Hofmann, K. P.
(2000)
J. Biol. Chem.
275,
1937-1943[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z. Kozmik, J. Ruzickova, K. Jonasova, Y. Matsumoto, P. Vopalensky, I. Kozmikova, H. Strnad, S. Kawamura, J. Piatigorsky, V. Paces, et al.
From the Cover: Assembly of the cnidarian camera-type eye from vertebrate-like components
PNAS,
July 1, 2008;
105(26):
8989 - 8993.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Anavi-Goffer, D. Fleischer, D. P. Hurst, D. L. Lynch, J. Barnett-Norris, S. Shi, D. L. Lewis, S. Mukhopadhyay, A. C. Howlett, P. H. Reggio, et al.
Helix 8 Leu in the CB1 Cannabinoid Receptor Contributes to Selective Signal Transduction Mechanisms
J. Biol. Chem.,
August 24, 2007;
282(34):
25100 - 25113.
[Abstract]
[Full Text]
[PDF]
|
 |
|